Catani and colleagues provide data on antigenic properties of neuraminidase proteins of pandemic H1N1 and show that antigenic diversity of the neuraminidase from 2009 to 2020 largely falls into two ...

One age group are more likely to have antibodies that bind to the H5N1 avian flu virus, new research has found.

Cidara Therapeutics (CDTX) announced the publication of preclinical data assessing CD388, the company’s influenza DFC, in the peer-reviewed ...

Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune statusSAN DIEGO, March 17, ...

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian influenza virus, according to new research from the Perelman School of Medicine ...

“As oseltamivir is the most widely used therapeutic and prophylactic against IAV, the continued circulation of viruses harboring NA-H275Y may necessitate a re-evaluation of influenza treatment ...

Not long after the first flu shot was introduced in 1945 by University of Michigan virologist Thomas Francis and his ...

Older adults who were exposed to seasonal flu viruses that circulated prior to 1968 are more likely to have some protection against H5N1, and children would benefit more from H5N1 vaccines.

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian ...

An in-house reverse-genetics generated H5N9 inactivated vaccine (SEP-22- N9) was evaluated for its vaccine efficacy in ...

New research suggests that past exposure to seasonal flu viruses may help protect people from severe illness caused by the ...

To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...